A computational solution to improve biomarker reproducibility during long-term projects
Authors:
- Feng FengFFFeng Feng
- Morgan P. ThompsonMTMorgan P. Thompson
- Beena E. ThomasBTBeena E. Thomas
- Elizabeth R. DuffyEDElizabeth R. Duffy
- Jiyoun KimJKJiyoun Kim
- Shinichiro KurosawaSKShinichiro Kurosawa
- Joseph Y. TashjianJTJoseph Y. Tashjian
- Yibing WeiYWYibing Wei
- Chris AndryCAChris Andry
- Deborah J. Stearns-KurosawaDSDeborah J. Stearns-Kurosawa
Preprint
Abstract
Biomarkers are fundamental to basic and clinical research outcomes by reporting host responses and providing insight into disease pathophysiology. Measuring biomarkers with research-use ELISA kits is universal, yet lack of kit standardization and unexpected lot-to-lot variability presents analytic challenges for long-term projects. During an ongoing two-year project measuring plasma biomarkers in cancer patients, control concentrations for one biomarker (PF) decreased significantly after changes in ELISA kit lots. A comprehensive operations review pointed to standard curve shifts with the new kits, an analytic variable that jeopardized data already collected on hundreds of patient samples. After excluding other reasonable contributors to data variability, a computational solution was developed to provide a uniform platform for data analysis across multiple ELISA kit lots. The solution (ELISAtools) was developed within open-access R software in which variability between kits is treated as a batch effect. A defined best-fit Reference standard curve is modelled, a unique Shift factor “S” is calculated for every standard curve and data adjusted accordingly. The averaged S factors for PF ELISA kit lots #1-5 ranged from −0.086 to 0.735, and reduced control inter-assay variability from 62.4% to <9%, within quality control limits. S factors calculated for four other biomarkers provided a quantitative metric to monitor ELISAs over the 10 month study period for quality control purposes. Reproducible biomarker measurements are essential, particularly for long-term projects with valuable patient samples. Use of research-use ELISA kits is ubiquitous and judicious use of this computational solution maximizes biomarker reproducibility.Keywords
All Related Versions
- Published version: PLOS ONE, 14 (4), e0209060.
This publication has 24 references indexed in Scilit:
- Return of Research Results to Study ParticipantsJAMA, 2018
- ELISA rescue protocol: Recovery of sample concentrations from an assay with an unsuccessful standard curveMethods, 2013
- Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population studyEuropean Radiology, 2012
- Believe it or not: how much can we rely on published data on potential drug targets?Nature Reviews Drug Discovery, 2011
- A Bayesian approach for estimating calibration curves and unknown concentrations in immunoassaysBioinformatics, 2010
- Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel AgentsClinical Cancer Research, 2010
- Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical TrialsPLOS Medicine, 2009
- Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter StudyAnalytical Chemistry, 2008
- Disclosing Individual Results of Clinical ResearchJAMA, 2005
- The five-parameter logistic: A characterization and comparison with the four-parameter logisticAnalytical Biochemistry, 2005